Business Description
Elicio Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US28657F1030
Description
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1 | |||||
| Equity-to-Asset | -0.5 | |||||
| Debt-to-Equity | -1.37 | |||||
| Debt-to-EBITDA | -0.57 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -50.7 | |||||
| 3-Year EPS without NRI Growth Rate | -55.1 | |||||
| 3-Year FCF Growth Rate | -46.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 30.38 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 88.69 | |||||
| 9-Day RSI | 72.66 | |||||
| 14-Day RSI | 64.29 | |||||
| 6-1 Month Momentum % | 32.14 | |||||
| 12-1 Month Momentum % | -30.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | |||||
| Quick Ratio | 3.4 | |||||
| Cash Ratio | 2.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.6 | |||||
| Shareholder Yield % | -14.73 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -2634.29 | |||||
| ROA % | -171.27 | |||||
| ROIC % | -310.04 | |||||
| ROC (Joel Greenblatt) % | -666.04 | |||||
| ROCE % | -250.79 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -1.4 | |||||
| EV-to-EBITDA | -1.43 | |||||
| EV-to-FCF | -1.7 | |||||
| Earnings Yield (Greenblatt) % | -71.43 | |||||
| FCF Yield % | -58.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Elicio Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -3.759 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 64.29 | ||
| 14-Day ATR (€) | 0.150879 | ||
| 20-Day SMA (€) | 4.7645 | ||
| 12-1 Month Momentum % | -30.63 | ||
| 52-Week Range (€) | 3 - 9.5 | ||
| Shares Outstanding (Mil) | 10.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Elicio Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Elicio Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Elicio Therapeutics Inc Frequently Asked Questions
What is Elicio Therapeutics Inc(FRA:9HA)'s stock price today?
The current price of FRA:9HA is €3.04. The 52 week high of FRA:9HA is €9.50 and 52 week low is €3.00.
When is next earnings date of Elicio Therapeutics Inc(FRA:9HA)?
The next earnings date of Elicio Therapeutics Inc(FRA:9HA) is 2025-03-28 Est..
Does Elicio Therapeutics Inc(FRA:9HA) pay dividends? If so, how much?
Elicio Therapeutics Inc(FRA:9HA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers